243 related articles for article (PubMed ID: 33675117)
21. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
22. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
[TBL] [Abstract][Full Text] [Related]
24. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
Wang J; Li HQ; Xu XH; Kong XC; Sun R; Jing T; Ye L; Su XF; Ma JH
Biomed Res Int; 2019; 2019():2682657. PubMed ID: 31950036
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.
Qie S; Li X; Wang X; Liu Y; Li J; Liu G
Endocrine; 2020 Jun; 68(3):508-517. PubMed ID: 31927749
[TBL] [Abstract][Full Text] [Related]
26. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
Anderson JE; Thieu VT; Boye KS; Hietpas RT; Garcia-Perez LE
Postgrad Med; 2016 Nov; 128(8):810-821. PubMed ID: 27488824
[TBL] [Abstract][Full Text] [Related]
27. Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
Xiao X; Wang C; Lai X; Zhang B; Gu L; Hou J; Zhou Z
J Diabetes Investig; 2020 May; 11(3):647-652. PubMed ID: 31758850
[TBL] [Abstract][Full Text] [Related]
28. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
29. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
Boye KS; Mody R; Wu J; Lage MJ; Botros FT; Woodward B
Clin Ther; 2018 Aug; 40(8):1396-1407. PubMed ID: 30093131
[TBL] [Abstract][Full Text] [Related]
30. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
Romera I; Conget I; Vazquez LA; Gentilella R; Lebrec J; Jódar E; Reviriego J
J Diabetes Complications; 2020 Jul; 34(7):107575. PubMed ID: 32220551
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
[TBL] [Abstract][Full Text] [Related]
32. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
[TBL] [Abstract][Full Text] [Related]
33. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
[TBL] [Abstract][Full Text] [Related]
34. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
Pollock RF; Norrbacka K; Cameron C; Mancillas-Adame L; Jeddi M
J Comp Eff Res; 2019 Mar; 8(4):229-240. PubMed ID: 30644328
[TBL] [Abstract][Full Text] [Related]
35. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
[TBL] [Abstract][Full Text] [Related]
37. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
38. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Dungan KM; Raz I; Skrivanek Z; Sealls W; Fahrbach JL
Diabetes Obes Metab; 2016 Jan; 18(1):49-55. PubMed ID: 26362460
[TBL] [Abstract][Full Text] [Related]
39. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
[TBL] [Abstract][Full Text] [Related]
40. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]